Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133209 · ClinicalTrials.gov registry record · NA
MRI Outcomes of Mindfulness Meditation for Migraine
A NA study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
NCT02133209: Completed NA study, sponsored by Johns Hopkins University.
NCT02133209 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 98 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02133209, a NA study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
Study Summary
112 migraine subjects will be initially randomly assigned to Mindfulness-Based Stress Reduction (MBSR) or a Stress Management for Headache group (SMH). Outcomes, including headache frequency and impact and brain activity, will be assessed at baseline, prior to intervention, and at 3-, 6-, and 12-months.
Primary Outcome
Headache days per 28 days and headache-related disability (HIT-6)
Interventions
- BEHAVIORAL Mindfulness Based Stress Reduction
- BEHAVIORAL Stress Management for Headaches
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-03 |
| Phase | NA |
What the finished NCT02133209 record still lists
NCT02133209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Mindfulness Based Stress Reduction is the first listed.
NCT02133209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02133209 about?
NCT02133209 is a clinical study titled "MRI Outcomes of Mindfulness Meditation for Migraine". 112 migraine subjects will be initially randomly assigned to Mindfulness-Based Stress Reduction (MBSR) or a Stress Management for Headache group (SMH). Outcomes, including headache frequency and impact and brain activity, will be assessed at baseline, prior to intervention, and at 3-, 6-, and 12-mon...
What is the current status of trial NCT02133209?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2014-05. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02133209?
The interventions under investigation include: Mindfulness Based Stress Reduction (BEHAVIORAL), Stress Management for Headaches (BEHAVIORAL).
Who is sponsoring clinical trial NCT02133209?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02133209's enrollment target sits among peer trials
98 922nd of 2000 higher than 1,078 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia